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Abstract: Abstract.: The Angelman syndrome (AS) is caused by genetic abnormalities affecting the
maternal copy of chromosome region 15q12. Until recently, the molecular diagnosis of AS relied on the
detection of either a deletion at 15q11-13, a paternal uniparental disomy (UPD) for chromosome 15 or
imprinting mutations. A fourth class of genetic defects underlying AS was recently described and consists
of mutations of the UBE3A gene. The vast majority of mutations reported so far are predicted to cause
major disruptions at the protein level. It is unclear whether mutations with less drastic consequences for
the gene product could lead to milder forms of AS. We report on our results obtained by screening 101
clinically diagnosed AS patients for mutations in the UBE3A gene. Non-stringent clinical criteria were
purposely applied for inclusion of AS patients in this study. The mutation search was carried out by
single-strand conformation polymorphism (SSCP), and SSCP/restriction fragment length polymorphism
(RFLP) analyses and revealed five novel UBE3A gene mutations as well as three different polymorphisms.
All five mutations were detected in patients with typical features of AS and are predicted to cause
frameshifts in four cases and the substitution of a highly conserved residue in the fifth. The results we
obtained add to the as yet limited number of reports concerning UBE3A gene mutations. Important
aspects that emerge from the data available to date is that the four classes of genetic defects known to
underlie AS do not appear to cover all cases. The genetic defect underlying approximately 10% of AS
cases, including some familial cases, remains unknown
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Abstract The Angelman syndrome (AS) is caused by ge-
netic abnormalities affecting the maternal copy of chro-
mosome region 15q12. Until recently, the molecular diag-
nosis of AS relied on the detection of either a deletion at
15q11–13, a paternal uniparental disomy (UPD) for chro-
mosome 15 or imprinting mutations. A fourth class of ge-
netic defects underlying AS was recently described and
consists of mutations of the UBE3A gene. The vast major-
ity of mutations reported so far are predicted to cause ma-
jor disruptions at the protein level. It is unclear whether
mutations with less drastic consequences for the gene
product could lead to milder forms of AS. We report on
our results obtained by screening 101 clinically diagnosed
AS patients for mutations in the UBE3A gene. Non-strin-
gent clinical criteria were purposely applied for inclusion
of AS patients in this study. The mutation search was car-
ried out by single-strand conformation polymorphism
(SSCP), and SSCP/restriction fragment length polymor-
phism (RFLP) analyses and revealed five novel UBE3A
gene mutations as well as three different polymorphisms.
All five mutations were detected in patients with typical
features of AS and are predicted to cause frameshifts in
four cases and the substitution of a highly conserved
residue in the fifth. The results we obtained add to the as
yet limited number of reports concerning UBE3A gene
mutations. Important aspects that emerge from the data
available to date is that the four classes of genetic defects
known to underlie AS do not appear to cover all cases.
The genetic defect underlying approximately 10% of AS
cases, including some familial cases, remains unknown.
Introduction
The Angelman syndrome (AS) is a neurological disorder
characterised by severe mental retardation, absence of
speech, paroxysms of laughter, epilepsy and abnormal en-
cephalographic activity (EEG; MIM 105830). The syn-
drome is caused by genetic abnormalities of an imprinted
region on chromosome 15q11.5. Before the role of the
UBE3A gene in AS was known, the molecular diagnosis
of the syndrome relied on the detection of approx. 80% of
cases, which fell into the following three categories: a
“common” 15q11–q13 deletion of about 4 Mb is detected
in approx. 65–70% of AS patients; a paternal uniparental
disomy (UPD) for chromosome 15 in 2–3% of cases; and
the occurrence of an imprinting defect is reported in about
3–5% of patients. The discovery of the role played by
UBE3A in the pathogenesis of the syndrome led initially
to the postulation that mutations in this gene could be 
responsible for the remaining approx. 20% of cases
(Kishino et al. 1997; Matsuura et al. 1997; Rougeulle et
al. 1997; Vu and Hoffmann 1997). The initial optimism
was, however, soon dampened by the detection of a lower
than expected frequency of mutations (Fang et al. 1999;
Malzac et al. 1998; Moncla et al. 1999a).
The UBE3A gene, also known as E6-AP, is an approx.
120-kb gene located in the AS critical region (Nakao et al.
1994). The UBE3A gene product is a ubiquitin-protein
ligase and catalyses the aggregation of ubiquitin to sub-
strates in E6-dependent pathways as well as E6-indepen-
dent pathways. The resulting protein complexes are a tar-
get for proteasome degradation (Huibregtse et al. 1993a;
Nawaz et al. 1999). Although the gene is expressed from
both alleles in a wide range of tissues, selective imprint-
ing was recently reported in brain (Rougeulle et al. 1997;
Vu and Hoffman 1997), whereby expression occurs only
from the maternal copy. Patients with mutations in the
UBE3A gene present with typical clinical AS features
(Jiang et al. 1999; Moncla et al. 1999a), such that the gene
is probably responsible for the major phenotypic manifes-
tations of the syndrome. Phenotypic differences are known
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to occur amongst AS patients (Bottani et al. 1994; Bürger
et al. 1996; Moncla et al. 1999a, 1999b). The most severe
forms of AS are usually found in patients with deletions,
followed by patients with UBE3A mutations; milder
forms of AS are described for patients with UPD15 and
imprinting mutations.
The majority of UBE3A mutations reported so far rep-
resent frameshift mutations or other insertions and dele-
tions that would lead to drastic consequences for the gene
product (Fang et al. 1999; Fung et al. 1998; Kishino et al.
1997; Malzac et al. 1998; Matsuura et al. 1997; Moncla et
al. 1999a; Tsai et al. 1998). It is still unclear whether DNA
mutations with less dramatic predicted changes at the
amino acid level might lead to milder forms of the syn-
drome. The work presented here aimed at providing a
screening for UBE3A mutations in a large number of clin-
ically assessed AS patients, which were selected accord-
ing to non-stringent criteria.
Subjects and methods
Subjects
Patients diagnosed by geneticists in our Institute or referred to us
over the past decade for molecular investigations of AS were in-
cluded in the study after exclusion of a 15q11–q13 deletion, pater-
nal UPD15 and an imprinting defect. A total number of 101 cases
have been analysed so far. In three patients the syndrome was fa-
milial, with two or more affected siblings.
The diagnostic criteria compiled by Williams et al. (1995) were
applied, wherever possible, in order to differentiate between pa-
tients with strong clinical AS features and those with mild to un-
certain phenotypes. Table 1 summarises the clinical features ob-
served in our group of AS patients. Precise clinical descriptions
were unfortunately not available for all patients referred to us, and
the very young age of some probands did not allow an assessment
of their psychomotor development.
Methods
The screening procedure for mutations in the UBE3A gene was at
first carried out by SSCP and SSCP/RFLP analysis. Further inves-
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Table 1 Summary of clinical features of a group of Angelman syndrome (AS) patients. Groups 1–4, typical AS features; groups 5–13,
mild AS features; group 14, unknown clinical features
Group Clinical findings Patients (n) Mutations/polymorphisms
1 Developmental delay, speech impairment, typical ataxic gait, 13 Including two 4 Mutations: AS298 (famil-
characteristic laughter, seizures, abnormal EEG, typical associated features familial cases ial), AS311, AS454, AS542 
(e.g. protruding tongue, wide mouth, hyperactivity of lower limbs) 1 Polymorphism: AS328
2 As group 1; however:
Abnormal EEG, no seizures 3 None
Normal EEG, seizures 2 None
Normal EEG, no seizures 5 None
3 No clinical details provided; however, patients seen by experienced 23 1 mutation: AS476
geneticists and defined as “typical”
4 Patients for whom only a few characteristics were provided
Developmental delay, speech impairment, associated features 1 None
(as in group 1)
Developmental delay and ataxic gait 1 None
Developmental delay, ataxia, seizures, abnormal EEG 1 None
Developmental delay, ataxia, seizures 1 Familial None
Developmental delay, ataxia, characteristic laughter, unclear EEG 1 None
Developmental delay, microcephaly 1 None
5 Patients with mild ataxia
Otherwise as group 1, without seizures 2 None
With developmental delay, characteristic laughter, mild to normal speech, 4 None
with or without seizures
With developmental delay and characteristic laughter 1 1 Polymorphism: AS520
Otherwise as group 1, with mild associated features 1 None
With developmental delay, speech impairment, abnormal EEG, no seizures 1 None
6 Patients with no characteristic laughter
Otherwise as group 1, with abnormal EEG and seizures 2 1 Polymorphism: AS446
Otherwise as group 1, with normal EEG and no seizures 3 None
With seizures and abnormal EEG, mild ataxia, mild speech problem 1 None
7 Patients with slightly impaired to normal speech
With developmental delay and characteristic laughter, with or without seizures 3 None
With ataxia, characteristic laughter, normal EEG, no seizures 1 None
8 Abnormal EEG with or without seizures 3 None
9 Developmental delay, ataxia with or without associated features and seizures 4 None
10 Differential diagnosis: AS/RETT syndrome 5 None
11 Differential diagnosis: AS/Prader-Willi syndrome 3 None
12 Differential diagnosis: mosaic trisomy 8 (negative)/AS 1 None
13 Differential diagnosis: fragile X syndrome (negative)/AS 2 1 Polymorphism: AS500
14 Referred to us, no clinical data provided 12 1 Polymorphism: AS259
tigations included DNA sequencing of the larger exons and long-
range PCR amplifications of genomic segments encompassing in-
tron sequences.
The individual exons of the coding region of UBE3A (exons
7–16) as well as exons 4 and 5 were amplified from genomic DNA
by polymerase chain reaction (PCR) using standard methods. The
PCRs consisted of 35 cycles of: a denaturing time of 30 s (3 min in
the first cycle) at 94°C, primer annealing at 50–56°C for 45 s, and
primer extension at 72°C for 1 min. The nucleotide sequences of
the primers used were as follows: exon 4, forward TGT ATT TCA
TT TAC AAT GACa, reverse TAA AGT GTT CTA ACC AAA
GGa; exon 5, forward TTT CTC TAG AAG TTT TTA TAA Ca,
reverse ATC GCA GAA AAT ATG ATC ACa; exon 7, forward
ATG GAA TAT TTT GCT AAC TG, reverse TAA GAA CCA
CAG TCT CAA CC; exon 8, forward GCT TAT TGT TTG AAT
GTT TGG, reverse GGT TTT CAG GCA ACA ATT CTC; exon
9, forward (a) GCA ACA GAG TAA ACA TAC ATA TT, for-
ward (b) TGC AGA CCA GAT TCG GAG, reverse (a) AAT GAA
TTC ACT GAA CTG TAT CAT G, reverse (b) TCT CCG AAT
CTG GTC TGC; exon 10, forward GCA ATC ATC TTC TTT
TCA TGT Tb, reverse CGA CAC CAT AAT CAC ATT ACb; exon
11, forward TTA AAA ATC ATT TCT TAT AGG, reverse GAA
TTA AAA AAA TGA CAA AG; exon 12, forward GCC TCA
ATT TAC CAT TTC TG, reverse AAT GAA GAG ACA AAA
TGT GAC; exon 13, forward (a) GAA GTT CTT GTG ATT AAT
GTa, forward (b) AAA ACA GTT CAA GGC TTT TCa, reverse
(a) CTT TAA GGG AGA TTC ATT GGa, reverse (b) CGA TAC
ATG ACT TTT TGC AGa; exon 14, forward AGT AGT ATA
GCA GAT AAC TAA GACa, reverse CCC TTT GGT GAA TCA
AAT CTT CCa; exon 15, forward GAA TGC CAA ACT GAA
ACC AG, reverse GTC ACA AGT TAA TAA TTA CC; exon 16,
forward ACC ATG ACT TAC AGT TTT CCTb, reverse TGG
GAC ACT ATC ACC ACC AAb.
Primers indicated by superscript a were synthesised according
to the sequences reported by Malzac et al. (1998), and those by su-
perscript b, according to Kishino et al. (1997). The other primers
were designed on the basis of the genomic sequences published by
Kishino and Wagstaff (1998). The oligonucleotide primers were
used in the unlabelled form for PCR and SSCP reactions, and la-
belled at the 5´ end with Cy5 for sequencing reactions.
The SSCP and SSCP/RFLP analysis were carried out using
standard methods. Aliquots of the PCR products representing ex-
ons 8 and 9 were digested with different restriction enzymes prior
to SSCP, as follows: exon 8 PCR products were digested sepa-
rately with XhoI and NdeII; exon 9 PCR products were digested
separately with TaqI, HinfI, MspI + AvaII + HaeIII + Sau3AI,
Tru9I, HinfI + XbaI + Sau3AI and DdeI + Sau3AI. The SSCP
analysis was carried out using a Genephor electrophoresis unit
(Pharmacia). DNA Sequencing reactions were performed using the
Pharmacia Cycle Sequencing Kit and were analysed using an ALF
automatic sequencer (Pharmacia). Long-range PCR amplifications
were carried out essentially as described above. The extension
time was increased to 2 min and the primers were chosen to cover
intron sequences.
Results
The screening for UBE3A mutations in our group of pa-
tients with suspected AS resulted in the detection and
characterisation of five novel UBE3A mutations and three
polymorphisms. The major characteristics of the eight
DNA variations are summarised in Table 2. All DNA
variations were detected by SSCP and SSCP/RFLP. Sys-
tematic DNA sequencing of the largest exons (exons 8, 9
and 16) in all patients did not reveal further DNA varia-
tions, nor were further mutations detected by the long-
range PCR analysis aimed at detecting larger deletions.
The first mutation listed in Table 2 represents the only
familial UBE3A mutation we have detected in our group
of AS patients so far. Two affected brothers, currently
aged 13 years and 10 years, inherited the same allele from
their asymptomatic mother. The mutation in this family as
well as those detected for patients AS 476 (a 9-year-old
girl) and AS 311 (a 15-year-old girl) are all predicted to
have drastic consequences at the protein level, leading in
each case to a frameshift and a truncated protein. The mu-
tation detected in the next patient (AS 454, a 9-year-old
girl) causes the substitution of a highly conserved amino
acid (Fig.1). The last UBE3A mutation that we found, de-
tected in an 8-year-old girl (AS 542), consisted in a short
tandem duplication of 16 bp, which is predicted to cause a
frameshift and an extension of the protein.
Three further DNA variations were considered as poly-
morphisms. The base substitution detected in patient AS
520 leads to the exchange of the alanine at codon 178 for
a threonine. Although this protein region is homologous
in humans and mice, it doesn’t seem to be highly con-
served in other species. However, the main argument in
favour of a polymorphism is obviously the paternal trans-
mission of the DNA variation. The second polymorphism
listed in Table 2 (detected in the DNA sample of patient
AS 259) is a T-to-C base substitution, which occurs at the
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Table 2 UBE3A mutations and polymorphisms detected in our group of clinically diagnosed AS patients. The nucleotide and codon po-
sitions refer to the complete UBE3A cDNA sequence, accession number U84404
Patient Exon DNA variation Predicted Familial/sporadic Comments
ID aa change
AS 298 8 762–763insGA Frameshift Familial: brother, affected; mother, carrier AS mutation
AS 454 9 2102 C to T Arg506Cys Sporadic: mother, no signs of mosaicism; father, normal AS mutation
AS 476 9 1296insT Frameshift Sporadic; mother, no signs of mosaicism; father, normal AS mutation
AS 311 11 2376delG Frameshift Sporadic; mother, no signs of mosaicism; brother, normal AS mutation
AS 542 16 3120ins16 Frameshift Sporadic: mother, no signs of mosaicism; father, normal AS mutation
AS 520 9 1118 G to A Ala178Thr Inherited from father Polymorphism
AS 259 12–13 Intron T to C No effect? Parental samples not available Polymorphism
AS 446 16 3´UTR del14a No effect? Inherited from mother Polymorphism
AS 500 16 3´UTR del14a No effect? Inherited from father Polymorphism
AS 328 16 3´UTR del14a No effect? Parental samples not available Polymorphism
aCorresponds to the polymorphism previously described by Fung et al. (1998)
9th base of the intron between exons 12 and 13. The
parental DNA samples were unfortunately not available.
The last polymorphism, a 14-bp deletion in the 3´UTR,
was detected in three unrelated patients. This DNA poly-
morphism corresponds to that reported by Fung et al.
(1998). The 14-bp deletion was present in the mother of
one proband (AS 446) and in the father of a second patient
(AS 500). Parental samples of the third proband (AS 328)
were unfortunately not available.
Discussion
We present the results obtained by screening clinically di-
agnosed AS patients for mutations in the UBE3A gene.
The type and frequency of mutations we detected are in
agreement with the results reported by other groups (Fang
et al. 1999; Fung et al. 1998; Kishino et al. 1997; Malzac
et al. 1998; Matsuura et al. 1997; Moncla et al. 1999a;
Tsai et al. 1998). The five heteroallelic mutations reported
here are all “private” mutations; they are located in four
different exons and do not appear to be clustered at “hot-
spot” regions, although they are all predicted to affect the
hect domain (Huibregtse et al. 1995). Two frameshift mu-
tations are located upstream of the hect domain, one
within the first half of the domain and the last towards the
3´ end of the domain. The fifth mutation, located at the 
5´ end of the hect domain, causes the substitution of a
highly conserved residue (R506C).
It is still unclear whether UBE3A mutations, which do
not directly involve the hect domain, may lead to milder
forms of the disorder. Interestingly, mild AS phenotypes
were observed by Matsuura et al. (1997) and Fang et al.
(1999) in siblings with a mutation that is not predicted to
affect the hect domain (C21Y). The missense mutation
S349P, detected by Malzac et al. (1998) in three brothers
with typical AS phenotypes, is localised within a UBE3A
region that is involved in the E6-dependent association
with p53 (Huibregtse et al. 1993b).
We intentionally did not apply stringent clinical criteria
for inclusion of AS patients in the study in order to inves-
tigate whether UBE3A mutations could also lead to
milder, non-typical AS-like cases. However, amongst the
101 patients we have screened so far, UBE3A mutations
were detected only in patients with typical features of AS
(Table 1). We are aware of the fact that probably less than
one-half of the patients referred to us for molecular inves-
tigations are indeed affected by AS. Based on the inci-
dences of AS patients with deletions and UPD15, we esti-
mated the frequency of UBE3A mutations in our group of
AS patients at about 9–10%. The number of UBE3A mu-
tations we detected in our group of patients is thus in
agreement with the frequency reported by other groups.
What emerges from the data available so far is that the ge-
netic defect underlying approximately 10% of all AS
cases remains unknown (Jiang et al. 1999). Amongst the
unsolved cases, we have patients with typical AS features,
including a couple of familial cases (Table 1).
The obvious questions are whether a large number of
UBE3A mutations remain undetected and whether there
are other “AS genes” that also lead to typical features of
the syndrome. DNA mutations, in UBE3A itself or other
genes, which would have repercussions on the transcrip-
tion and expression of the UBE3A gene would be particu-
larly difficult to detect and would have been missed in our
screening. The major difficulties in carrying out the muta-
tion search at the cDNA level is the biallelic expression of
the gene in the majority of tissues, the low expression of
the gene in blood (Kishino and Wagstaff 1998), and the
presence of at least two highly homologous processed
pseudogenes (Kishino and Wagstaff 1998).
It is as yet unclear how an abnormal expression in
brain of the UBE3A gene leads to the complex phenotypes
typical for AS. Major challenges in the field will be to
provide a better understanding of the UBE3A gene in AS
and animal models and to reveal the genetic defects un-
derlying the remaining 10% or so of unsolved AS cases.
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Fig.1 The amino acid substitution at codon 506 in patient AS454
results in the modification of a highly conserved protein residue.
The amino acid sequences reported here represent: a*, human
ubiquitin protein ligase E3A (U84404), residues 492–521; b*, E6-
AP ubiquitin protein ligase (AF082835), residues 489–518; c*,
E6-AP ubiquitin protein ligase (U82122), residues 489–518; d*,
putative ubiquitin-protein ligase (ALO32684), residues 429–447;
e*, hypothetical 103.5-kd protein (sp/P40985/YJ06), residues
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